Cytokine regulation of immune tolerance

Burns and Trauma

Volumn 2, Issue 1, 2014, Pages 11-17

  Wu, Jie ^a   Xie, Aini ^a   Chen, Wenhao ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Cytokine; immune tolerance; regulatory T cell; T cell differentiation

Indexed keywords

EID: 85011995676     PISSN: None     EISSN: 23213876     Source Type: Journal    
DOI: 10.4103/2321-3868.124771     Document Type: Review

References (49)

1. Nurieva RI, Liu X, Dong C. Molecular mechanisms of T-cell tolerance. Immunol Rev 2011;241:133-44.
2. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009;27:591-619.
3. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008;26:453-79.
4. Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptidespecific CD4(+) T cell responses. Proc Natl Acad Sci U S A 1999;96:8603-8.
5. Banchereau J, Pascual V, O'Garra A. From IL-2 to IL-37: The expanding spectrum of anti-inflammatory cytokines. Nat Immunol 2012;13:925-31.
6. Letterio JJ, Roberts AB. Transforming growth factor-beta1-deficient mice: Identification of isoform-specific activities in vivo. J Leukoc Biol 1996;59:769-74.
7. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359:693-9.
8. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99-146.
9. Li MO, Sanjabi S, Flavell RA. Transforming growth factorbeta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006;25:455-71.
10. Marie JC, Liggitt D, Rudensky AY. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cellspecific targeting of transforming growth factor-beta receptor. Immunity 2006;25:441-54.
11. Wahl SM. Transforming growth factor-beta: Innately bipolar. Curr Opin Immunol 2007;19:55-62.
12. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011;29:71-109.
13. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 2009;10:1178-84.
14. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
15. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008;28:546-58.
16. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 2011;34:566-78.
17. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006;4:754-9.
18. McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, Taylor KD, et al. NIDDK IBD Genetics Consortium. Genomewide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010;42:332-7.
19. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002;16:779-90.
20. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006;7:937-45.
21. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006;7:929-36.
22. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, et al. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 2010;11:854-61.
23. Ilarregui JM, Croci DO, Bianco GA, Toscano MA, Salatino M, Vermeulen ME, et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 2009;10:981-91.
24. Mascanfroni ID, Yeste A, Vieira SM, Burns EJ, Patel B, Sloma I, et al. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol 2013;14:1054-63.
25. Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, et al. IL-37: A new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 2011;22: 127-47.
26. McNamee EN, Masterson JC, Jedlicka P, McManus M, Grenz A, Collins CB, et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A 2011;108:16711-6.
27. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010;11:1014-22.
28. Khattar M, Chen W, Stepkowski SM. Expanding and converting regulatory T cells: A horizon for immunotherapy. Arch Immunol Ther Exp (Warsz) 2009;57:199-204.
29. -cell activation. Immunol Lett 2010;132:61-8.
30. Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, Watford WT, et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 2007;109:4368-75.
31. Lio CW, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity 2008;28:100-11.
32. Guo Z, Khattar M, Schroder PM, Miyahara Y, Wang G, He X, et al. A dynamic dual role of IL-2 signaling in the twostep differentiation process of adaptive regulatory T cells. J Immunol 2013;190:3153-62.
33. Chen W, Xie A, Chan L. Mechanistic basis of immunotherapies for type 1 diabetes mellitus. Transl Res 2013;161:217-29.
34. Hulme MA, Wasserfall CH, Atkinson MA, Brusko TM. Central role for interleukin-2 in type 1 diabetes. Diabetes 2012;61:14-22.
35. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010;207:1871-8.
36. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, et al. Diabetes TrialNet and the Immune Tolerance Network. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012;61:2340-8.
37. Gregersen PK, Olsson LM. Recent advances in the genetics of autoimmune disease. Annu Rev Immunol 2009;27:363-91.
38. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-9.
39. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010;11:1093-101.
40. Xie A, Buras ED, Xia J, Chen W. The Emerging Role of Interleukin-21 in Transplantation. J Clin Cell Immunol 2012;Suppl 9:1-7.
41. Bubier JA, Sproule TJ, Foreman O, Spolski R, Shaffer DJ, Morse HC 3rd, et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A 2009;106:1518-23.
42. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R. Fc reduces disease progression. J Immunol 2007;178:3822-30.
43. Sutherland AP, Van Belle T, Wurster AL, Suto A, Michaud M, Zhang D, et al. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 2009;58:1144-55.
44. McGuire HM, Walters S, Vogelzang A, Lee CM, Webster KE, Sprent J, et al. Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 2011;60:867-75.
45. Vignali DA, Kuchroo VK. IL-12 family cytokines: Immunological playmakers. Nat Immunol 2012;13:722-8.
46. Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, et al. T-bet is rapidly induced by interferongamma in lymphoid and myeloid cells. Proc Natl Acad Sci U S A 2001;98:15137-42.
47. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (∗). Annu Rev Immunol 2010;28:445-89.
48. van de Vosse E, Haverkamp MH, Ramirez-Alejo N, Martinez-Gallo M, Blancas-Galicia L, Metin A, et al. IL-12Rbeta1 Deficiency: Mutation update and description of the IL12RB1 variation database. Hum Mutat 2013;34:1329-39.
49. +T cells. Immunol Lett 2010;128:116-23.